Trial · NCT07391566
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase Ib: Dose-limiting toxicities (DLTs) | From the first dose of study drug treatment through Cycle 1 (28 days) | |
| Primary | Phase Ib: Maximum tolerated dose (MTD) | From the first dose of study drug treatment through Cycle 1 (28 days) | |
| Primary | Phase 1b: Recommended Phase 2 Dose (RP2D) | From the first dose of study drug treatment through Cycle 1 (28 days) | |
| Primary | Phase 2: Overall response rate (ORR) | Approximately 2 years | |
| Secondary | Phase 1b: Overall response rate (ORR) | Approximately 2 years | |
| Secondary | Duration of response (DOR) | Approximately 2 years | |
| Secondary | Disease control rate (DCR) | Approximately 2 years | |
| Secondary | Progression-free survival (PFS) | Approximately 2 years | |
| Secondary | Overall survival (OS) | Approximately 2 years | |
| Secondary | Maximum plasma concentration (Cmax) | From Pre-dose of Cycle 1 Day 1 and up to Cycle 1 Day 9 (Approximately 10 days, each cycle is 28 days) | |
| Secondary | Time to maximum plasma concentration (Tmax) | From Pre-dose of Cycle 1 Day 1 and up to Cycle 1 Day 9 (Approximately 10 days, each cycle is 28 days) | |
| Secondary | Area under the plasma concentration-time curve (AUC) | From Pre-dose of Cycle 1 Day 1 and up to Cycle 1 Day 9 (Approximately 10 days, each cycle is 28 days) | |
| Secondary | Elimination half-life (t1/2) | From Pre-dose of Cycle 1 Day 1 and up to Cycle 1 Day 9 (Approximately 10 days, each cycle is 28 days) | |
| Secondary | Trough observed plasma concentration (Ctrough) | From Pre-dose of Cycle 1 Day 1 and up to Cycle 1 Day 19 (Approximately 20 days, each cycle is 28 days) | |
| Secondary | Adverse Events (AEs) | Approximately 2 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07391566/registered